

N **PSYCHOPHARMACOLOGY** NEWSLETTE R **AND SUBSTANCE ABUSE**

Volume 25, Number 1

Division 28 - The American Psychological Association

Spring, 1992

PRESIDENT'S LETTER

Ronald W. Wood
President, Division 28

We recently renamed the division to add "and Substance Abuse"; this happened as the issue of prescription privileges for psychologists escalated into prominence. Our membership chair reports a large number of new applicants, perhaps a growth as large as 25%!

Who are we? What are we becoming?

Although *Webster's* differs, we have been defining psychopharmacology as the study of medicines, drugs and chemicals, and their effects on human and animal behavior. We are inherently an applied scientific division. An alternative definition would be to ask who we are, we who define the division by joining it. So I turned to the profile of our membership prepared in 1989 by the APA Office of Demographic, Employment and Educational Research (ODEER). We will be surveyed again by this group later this year, so I offer you a snapshot of that survey, last summarized by former President Robert Balster:

→ As a group, we are 20 years past our highest degree. 34% of us earned degrees as health service providers and half as research psychologists--18.5% experimental, 11% physiological. Twenty years later, 32% of us characterized our work as "health provider", 9.5% as "experimental"; 8.4% "physiological"; and 12.5% "psychopharmacology."

→ Of those reporting being employed full-time, 63% conduct research, 56% are licensed or certified, and 53% provide health/mental health services. Where do we work? 26.6% in University settings, 13.2% in medical schools, 4.5% in colleges, 18.4% in independent practice, and 11.2% in hospitals.

→ Membership in other divisions: 21% are in Clinical (12), 13.5% in Psychotherapy (29), and 13.9% in Clinical

Neuropsychology (40); 6.8% are ABPP Diplomats in Clinical. On the other hand, 21% are in Physiological/Comparative (6), 17.3% in EAB (25), and 14% Experimental (3).

The Research Dollar

Yet another way to characterize who we are is to describe the economic determinants of our behavior. We are a scientific division with an applied orientation, and 60% of us are involved in research. Thus, what we do on a daily basis is determined not by our employer but by external funding agencies.

APA has taken what might be termed a "supply side" approach to the funding picture, tracking the agencies that provide research funding. APA has paid great attention to NIMH and NSF; over the past few years, their interest in NIDA has increased. APA has taken as its charge to identify existing funding streams, emerging issues, and targets of opportunity, and to pursue advocacy activities accordingly.

What has been lacking, however, is a "demand-side" analysis of our funding. This fact became obvious to me when I tried to determine where the members of our division obtained their research monies. The degree of the awardee is accessible in some government databases, but being a "psychologist" does not make one a "psychopharmacologist." We contemplated a survey asking YOU where you got your money in the past, where you get it now, and perhaps most importantly, where you would like to get it in the future, as well as some demographic and current funding information. I was amazed that our membership organization does not have this information. They certainly have a talented group in ODEER, and demographic information on all of us. Discussions are underway with ODEER, Division Services, and the Policy Office. There is no question that this information would be helpful in focusing advocacy efforts on our existing portfolios, and on where our membership would like to focus their future research efforts--i.e., obtain their support.

(cont. on p. 3)

PROFILES OF CANDIDATES FOR DIVISION 28 OFFICE

In mid-May, you will receive a ballot asking you to vote for two Division 28 officers, President-Elect and Member-at-Large. The winners of these elections will take office in August, 1992. The President-Elect will then serve as President in 1993-94 and as Past-President in 1994-95. Members-at-Large, whose job is to represent the general membership at Executive Committee meetings, serve for three-year terms. Profiles of the candidates are presented below.

President-Elect

LEWIS SEIDEN. Education: Ph.D. in psychology and biochemistry, University of Chicago, 1962. Research interests: relationship among monoamines, behavior, and drug action; application of computer technology to the analysis of electrophysiological and behavioral data; neuro- and psychopharmacology of antidepressant drugs and of amphetamine and related phenethylamines that have toxic effects on the central nervous system. Current position: Professor of Physiological and Pharmacological Sciences, Psychiatry, University of Chicago. Memberships: APA (Fellow, Division 28), American Association for the Advancement of Science (Fellow), American College of Neuropharmacology (Fellow), New York Academy of Sciences, Society of Biological Psychiatry, American Society for Pharmacology and Experimental Therapeutics; Service positions: NIDA, Drug Abuse Biomedical Research Review Committee; Biochemistry Research Subcommittee; NIMH, Neuropsychology Research Review Subcommittee of the Basic Psychopharmacology and Neuropsychology Research Review Committee; Merit Review Board in Neurobiology, Veterans Administration; Research Scientist Development Review Committee. Platform: 1) A primary issue is the continuing change in the field, and the need to encourage our students to become educated in recent advances in molecular biology, computer technology, etc. 2) Division 28 needs to move rapidly to form a subcommittee to study the question of clinical psychologists writing prescriptions for psychotropic drugs, so that sensible decisions regarding the long and short range role of psychologists can be made. 3) Animal regulations as spurred on by animal-welfare activists will continue to be an issue and one in which we must certainly play a key role. 4) The relationship of Division 28 to other Divisions within APA and to the APA Scientific Directorate will also be crucial in order to ensure that APA remains a viable scientific and clinical organization.

MARIAN W. FISCHMAN. Education: Ph.D. in biopsychology, University of Chicago, 1972. Research Interests: behavioral pharmacology, variables controlling drug taking in humans, evaluation of potential pharmacological interven-

tions for treating drug abuse, control of eating behavior. Current position: Professor, Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine. Memberships: APA (Fellow, Division 28), American College of neuropsychopharmacology (Fellow), American Psychological Society (Fellow), Behavioral Pharmacology Society, American Society for Pharmacology and Experimental Therapeutics, Society of Behavioral medicine. Service positions: APA Committee on Research Support (1985-1989); Division 28 Program Chair (1977); Division 28 Executive Committee (1986-1989); NIDA Clinical Behavioral Review Committee (1980-1984), Chair 1983-84); Ad hoc reviewer NIDA, NIH, VA; national Research Council Committee on Space Biology and Medicine Panel on Human Behavior (1984-1986); National Research Council Commission on Behavioral and Social Sciences, Committee on Drug Use in the Workplace (1991-pres); Committee on Problems of Drug Dependence (1983-1987); American Council for Drug Education Advisory Board; Ciba Foundation Scientific Advisory Committee; Board of Scientific Counselors of the NIDA Addiction Research Center (1985-1989); Editorial reviewer *J. Pharm. Exp. Ther.*, *Psychopharm.*, *Drug and Alc. Dep.*, *Archives of Gen. Psychiat.*, *Br. J. Addict.* Platform: Foci for Division 28 activities include: 1) development of a new journal which leads and represents the field, 2) advocacy of responsible research evaluating drug and medication effects using both human and non-human subjects through providing information about the contributions of that research and by monitoring and communicating regulations, 3) responsibility to the issue of prescription writing privileges for psychologists to insure their adequate training, 4) continued focus on the importance of supporting graduate training in psychopharmacology and substance abuse, and 5) monitoring and working for changes in funding patterns for research and training in psychopharmacology and substance abuse.

Member-at-Large

DEBORAH CORY-SLECHTA. Education: Ph.D. in Psychology, University of Minnesota, 1977. Research interests: relationships between neurotransmitters and behavior and how such relationships are altered by exposures to environmental toxicants such as lead. Current position: Associate Professor of Toxicology and of Pediatrics, University of Rochester School of Medicine and Dentistry. Memberships: APA (Division 28, Fellow), Society for Neuroscience, Behavioral Pharmacology Society, Behavioral Toxicology Society, Society of Toxicology, Society for the Stimulus Properties of Drugs. Service Positions: Environmental Health Sciences Review Committee, National Institute of Environmental Health Sciences (1985-1989); Superfund Hazardous Substances Basic Research Program Review

(cont. on p. 3)

Committee (1987-1991); Ad-hoc reviewer, Toxicology study section and Human Development and Aging study section; Program Co-Chair, 9th International Neurotoxicology Conference; New Dimensions of Lead Neurotoxicity; Redefining Mechanisms and Effects (1991); Member FIFRA Scientific Advisory Subpanel on Neurotoxicity Test Guidelines, Environmental Protection Agency (1987); Reviewer, Toxicological Profile on Lead, Agency for Toxic Substances Disease Registry (1987-1990); President, Neurotoxicology Specialty Section, Society of Toxicology (1992); Secretary-Treasurer, Behavioral Toxicology Society (1983-1986); Editorial Boards; *NeuroToxicology* (Associate Editor), *Neurotoxicology and Teratology*, *Fundamental and Applied Toxicology*; Reviewer for: *Journal of Pharmacology and Experimental Therapeutics*, *Psychopharmacology*, *Brain Research Bulletin*, *Pharmacology and Toxicology*, *Pharmacology Biochemistry and Behavior*, *Behavioral Pharmacology*, *Toxicology and Applied Pharmacology*, *Toxicology*, *American Journal of Mental Deficiency*, *Biochemical Toxicology*, *Environmental Research*, *Biological Trace Element Research*. **Platform:** In a time of shrinking budgets and diverted priorities, Division 28 needs to be particularly vigilant in efforts to maintain an active role in support of funding for basic and clinical research in the area of psychopharmacology and substance abuse as a basis for treatment approaches. In conjunction with that, the continued involvement of Division 28 in other related agendas should be reinforced, including those pertaining to the use of animals in research, and regulation of neurotoxic chemical exposures, i.e., the behavioral pharmacology of uninvited chemical treatments.

JAMES L. SORENSEN. Education: Ph.D. in Psychology, University of Rochester, 1975. **Research Interests:** Treatment research in substance abuse and community psychology, prevention and treatment of AIDS among drug abusers. **Current Position:** Chief, Substance Abuse Services, University of California, San Francisco at San Francisco General Hospital; Adjunct Professor, Department of Psychiatry, UCSF. **Memberships:** APA, AAAS, APA Task Force on Drug Abuse Policy (1986), APHA, International AIDS Society, Society of Psychologists in Addictive Behaviors. **Service Positions:** Panel of Experts, Methadone Framework Project, UCLA Drug Abuse Research Group, 1991-1992; University-wide Task Force on AIDS, 1989-present; Advisory Group on Methadone Treatment Quality Assurance System, Research Triangle Institute, 1990-present; Reviewer, Social & Behavioral Science Track, VII International Conference on AIDS, 1990-1991; Social Sciences & Public Policy Planning Committee, VI International Conference on AIDS, 1989-1990; Scientific Advisory Committee, American Foundation for AIDS Research, 1989-present; Technical Panel on Research & Intervention Strategies, Committee on AIDS Research in the Behavioral, Social, & Statistical

Science, National Research Council, 1989; Congressional Briefing on drug abuse research, APA 1988; Editorial boards of *Journal of Community Psychology*, 1990-present, and *Psychology of Addictive Behaviors*, 1992. **Platform:** Division 28 must take the initiative in promoting increased training about substance abuse and psychopharmacology in undergraduate, graduate, and postgraduate psychology training programs. We must also place greater emphasis on attracting new members into this division, especially those involved in clinical research.

APPOINTED OFFICERS OF DIVISION 28: CALL FOR NOMINATIONS

Appointed officers of Division 28 include the secretary, treasurer, program chair, membership chair, newsletter editor, and professional society liaisons. Among the offices needing to be filled in August, 1992 include the secretary (Stephen T. Higgins, the current secretary, has submitted his resignation) and program chair for 1994. (Note: The 1994 Convention will be held on August 12-16 in Los Angeles. Experience dictates the desirability of the Program Chair's residing in a geographically compatible location.) If you wish to nominate yourself or someone else for one of these positions, please get in touch with Ronald Wood, President of Division 28, Institute of Environmental Medicine, New York University Medical Center, 550 First Ave., New York, NY 10016; tel. (914) 351-4249; email WOOD@NYUMED. The list of candidates will be presented for consideration at the Fall meeting of the Executive Committee.

PRESIDENT'S LETTER (cont.)

The National Institute of Mental Health

Many of us were trained during or shortly after the "psychopharmacology revolution" in laboratories funded by the NIMH. There were active initiatives in the 1970's in behavioral and psychopharmacology; striking advances were being made in the study of substance abuse, and NIDA was born from NIMH. Many of us moved our funding and research interests in that direction. Superb study sections evolved at NIDA, while at NIMH the psychopharmacology research portfolio has diminished enormously. The Psychopharmacology Research Branch is leaderless. We have included the description of the vacant position (see below). This is a responsible position that we hope will be filled soon; this individual is responsible for stimulating research initiatives and fostering the research portfolio on psychopharmacology at NIMH.

(cont. on p. 4)

PRESIDENT'S LETTER (cont.)

Frederick Goodwin, M.D. appointed NIMH Director

Dr. Frederick Goodwin has been appointed NIMH Director. As you know, Dr. Goodwin has had a distinguished research career; as you may not remember, he was the recipient of the APA Psychopharmacology award, given by our division 20 years ago. Under the ADAMHA reorganization plan put forth and discussed intensively last year, Dr. Goodwin was to assume leadership of the NIMH with the reorganization of ADAMHA.

Dr. Goodwin assumes this position in the midst of controversy. At an NIMH Advisory Council meeting, he described a new initiative on violence. Some members of the audience took offense at his remarks; thus, the remarks were insensitive by definition, and Goodwin apologized publicly and repeatedly--e.g., "...the increase in homicide and interpersonal violence has reached the level of a public health emergency. My remarks were aimed at pointing out the need to attack these problems with a full range of scientific investigations, ranging from basic research through community studies. In an effort to shed light on the violence problem, I juxtaposed primate research to the problems in our cities in a careless way. I regret this insensitivity...." He subsequently resigned his Presidential appointment as ADAMHA Director. (As these events unfolded, news items were posted on DIV28@GWUVM for our subscribers.)

Strongly critical letters emerged from Reps. Dingel, Conyers, and Sen. Kennedy. From the Conyers letter: "...Dr. Goodwin's comments are, of course, subject to different interpretations. One interpretation is that Dr. Goodwin believes that inner city black youth are essentially animals, whose behavior mirrors that of primates and who must be rescued from their jungle-like environment.... [I]t is imperative that all segments of the public have confidence that the policies of the agency responsible for handling all of the federal funds for drug treatment are not tainted by racism...." An inquiry was then lodged about details of the NIMH research portfolio. Senator Kennedy's letter stated: "...Primate research is a preposterous basis for discussing the crime and violence that plagues our country today...."

On behalf of the Division, I promptly wrote to Secretary Sullivan "...to express our concern and our willingness to provide expertise in addressing the relevance of primate research to the human condition...."

Ray Fowler, the APA CEO has recently written to the Senator, and to his cosignee Rep. Dingell, expressing our concern "...that this statement minimizes the important contribution of primate research to our understanding of human

behavior.... [Caveats do] not negate the importance of behavioral research with animals and its relevance to the study of the human condition. There is a large body of scientific research on alcohol, drugs of abuse, aggression, and violence which uses animal models. This research has led, for example, to an increased understanding of the mechanisms of drug abuse and addiction in humans. Many animal species, including nonhuman primates, are used in this research. There is also a long, distinguished scientific record on behavioral research in primates, that has provided insights to those grappling with the evolutionary component of human behavior and social organization...." The division appreciates this action by Dr. Fowler on our behalf.

The APA Board of Directors was meeting in Washington as these events unfolded, and weighed in opposing Dr. Goodwin's appointment in a carefully crafted letter to Dr. Sullivan. I remarked by email to the division, "No professional association can speak with unanimity, or they would not be able to speak at all. The directors express what they judge to be in our best interest; I support the mechanism and the Association, if not the present action...."

William Greenough wrote to Secretary Sullivan dissociating himself "...as a member of the American Psychological Association, from its position with regard to Dr. Frederick K. Goodwin's tenure as Director of NIMH.... There is simply not a shred of evidence in my interactions with Fred Goodwin of racist sentiments. His views are, in fact, quite the opposite.... I believe I speak for many of my American Psychological Association colleagues in repudiating the APA stand...and strongly supporting Frederick Goodwin's retention as NIMH Director." Joseph Coyle, the President of the Society for Neuroscience and an NIMH Advisory Council member, was present when Dr. Goodwin made his comments. He wrote a very strong letter in support of Dr. Goodwin to Secretary Sullivan. He stated that primate models of the type described move us away from genetic conceptualizations that can be used to encourage racist misrepresentations. The AMA and the other APA weighed in with their expressions of support for Dr. Goodwin.

I had collected press releases, articles, and other statements of Dr. Goodwin's because of his leadership in opposing animal activism. I wrote a detailed letter to Rep. Conyers on my letterhead rebutting the charge of racist beliefs, providing numerous examples (and a videotape) to the contrary. "...It is my hope that any misunderstanding of Dr. Goodwin's thoughts and actions on issues of racial discrimination come to an end. Dr. Goodwin has had a distinguished biomedical research career in which he has made significant contributions to the public health. May he continue to do so."

(cont. on p. 5)

PRESIDENT'S LETTER (cont.)

This was a complex and trying time, coping with a no-win issue where individuals did as they thought best, or in their perceived self-interest. As it is, there are bruised feelings all around.

To subscribe to the Division's Discussion List, you need access to BITNET or INTERNET. Send a message, SUB DIV28 Firstname Lastname, to LISTSERV@DIV28. Problems? Contact your local wizards or Cheri Fullerton.

APA COUNCIL MEETING, WINTER 1992

Steve Fowler

Division 28 Representative to Council

The APA Council of Representatives convened in Washington, D.C. to fulfill their fiduciary responsibilities to the membership. I use the word "fiduciary" here because it was uttered repeatedly in the Council's deliberations about a variety of issues having legal and financial implications. Among the highlights of the meeting were (1) a visit to and tour of APA's new building, (2) a report on the preference of the membership for an annual convention date, (3) extensive debate regarding the Divisions' separate prerogatives as these may be limited and reviewed by APA governance as a whole, (4) lengthy and detailed (i.e., word-by-word) discussion of the Revised Ethical Principles for Psychologists, (5) approval of the 1992 \$46 million budget.

APA's new building at 750 First Street, Washington, D.C., is nothing short of magnificent. The modernist exterior is matched by a well-appointed interior that makes use of natural materials such as marble, granite, and hardwoods. Truly skilled craftsmanship of this quality is rare in the modern world. Office space available for non-APA functions is already 98% rented. The leadership appears to have made a wise long-term investment that should increase APA's financial resources in a way that inhibits the growth rate of annual dues. If you attend the centennial convention in August, plan to visit APA's impressive new headquarters.

As you may recall, a Convention Survey accompanied the last apportionment ballot. The results of the survey suggest that respondents (who were deemed representative of the membership) favored early August for the convention date, with the first week receiving the largest percentage of preferences. Thus, a change in date appears unlikely. Council addressed the issue of Divisional autonomy. Both legal counsel and cogent remarks of Council members led to the adoption, despite some vocal dissent, of a resolution that strengthens APA's oversight and approval of any standards

or guidelines originated by individual divisions. The resolution also called for a review of current APA bylaws with the aim of eliminating ambiguities and contradictory statements. Both parts of the resolution appeared to be motivated by legal advice to limit APA's potential financial liability.

Much of the Council's time was devoted to a discussion of the current draft of the Revised Ethical Principles for Psychologists. Before the meeting I received many communications, from Coalitions and from concerned individuals, urging me to neither support nor move adoption of the Ethical Principles draft. By consensus, Council agreed that no one intended that the current draft be the final one. As a result, the discussion and debate took the form of suggesting refinements of language to be incorporated into the next draft that will be presented in the *Monitor* to the membership for comment before the August meeting of the Council, at which time the Revised Principles will be voted up or down. One dimension of disagreement was the degree to which the Principles should be aspirational and therefore general as opposed to detailed and prescriptive of specific behaviors. The draft under consideration contained some of both. Among the diverse issues discussed were sexual harassment, limitations on the time interval after termination of therapy that would make therapist-patient sexual relations no longer unethical (2 years seemed to be the consensus!), and the use and interpretation of test results. Although not discussed by Council (because it ran out of time), the draft Revised Principles contains changes of import to academic psychologists. For example, with regard to publication credit the new Principles version says that a publication emanating from a student's thesis or dissertation must list the student as an author, but the student does not have to be first author of the dissertation if circumstances warrant this (i.e., the student shows no interest in taking the lead in publishing the results). Please read the revised Ethical Principles draft when it is published in the *Monitor* and send me your comments.

I have no specific recommendations to make as to which of the candidates for APA President would best serve the Division's interests. When next year's call for nominations is issued, however, I suggest that you specify Kurt Salzinger as your nominee. He is currently Division 25 Council Representative and is seeking election to the APA Board of Directors (only Council members vote). He is a very able and articulate representative for science and academic interests, and as former President of the NY Academy of Sciences, he is highly qualified to be APA President. He has indicated that he would be responsive to a draft.

If you have questions about Council, the Ethical Principles draft, budget, etc., or issues for me to present to Council, write or call: Stephen C. Fowler, Dept. of Psychology, U. of MS, University, MS 38677; tel (601) 232-7383.

CONVENTION 1992, WASHINGTON, DC

Nancy Ator

1992 Program Chair, Division 28

The 1992 Division 28 Program was hand-delivered to the new APA Headquarters building mid-February. The short abstracts of accepted presentations were sent to *Pharmacology Biochemistry and Behavior* to be published in the June issue.

The number of submissions to Division 28 increased significantly over last year. A full and varied program including reports on basic behavioral pharmacology/psychopharmacology, neurobehavioral toxicology, public policy issues in use of research results, etiology of substance abuse, pharmacological and environmental factors related to substance abuse treatment, and reports on drug abuse treatment projects, among others, have been arranged. Thanks to Maxine Stitzer, David Penetar, Harriet deWit, and Richard Foltin for their help in reviewing this year's submissions to Division 28. A workshop proposal on Child and Adolescent Psychopharmacology: Update for Clinical Psychologists also was submitted to the Division for endorsement in conjunction with the proposal's submission to the APA Continuing Education Committee. Thanks to Robert Sprague, Marlyne Kilbey, Maxine Stitzer, Chris-Ellyn Johanson, and Ron Wood for reviewing this proposal.

The number of hours of "Division 28" programming was increased by the co-sponsorship of symposia with Divisions 6 (Comparative and Physiological), 12 (Clinical), and 25 (Experimental Analysis of Behavior). The Division 28 poster session will be co-sponsored by Divisions 3 (Experimental), 6, and 25 and will include a social hour as well. Additional social hours also have been arranged with these Divisions.

In other collaborative efforts, an invited symposium organized by President-Elect Maxine Stitzer on pharmacological adjuncts in the treatment of alcoholism has been included in a Science-Practice Weekend initiative organized by Thomas Boll. Past-President Klaus Miczek was selected to give an Invited Address under the Science Weekend theme of "Stress and Health: Human and Animal Approaches." A symposium submitted to Division 28 by Tony Strickland of Drew University of Medicine and Science on inter-ethnic psychopharmacology (and co-sponsored by Division 12, Section VI) will be part of the Ethnic Minority Miniconvention. As part of the Centennial celebration, Division 28 is highlighting a symposium organized by Centennial Officer Herb Barry, "Present at the Creation of Division 28," in which past presidents and a Distinguished Affiliate of the Division will speak.

OPEN POSITIONS

Chief, Psychopharmacology Research Branch, National Institute of Mental Health; Division of Basic Brain & Behavioral Sciences; Psychopharmacology Research Branch; GM-15: Incumbent is responsible for planning, developing, and administering programs of support for the Psychopharmacology Research Branch. Applicant is responsible for analyzing current research activities; identifying extramural research areas of underdevelopment; and stimulating submission of grant applications in the Branch. Position is available immediately; salary \$64,233-\$83,502. Applicants must document possession of state-of-the-art knowledge of advanced theories, principles, emerging trends, methods, and techniques pertaining to the biological and behavioral sciences, and skill in applying this knowledge to the study of psychopharmacologic research. Postdoctoral (or equivalent) research in this related field is also required. Representative: Stephen H. Koslow, Ph.D., Dept. of Health and Human Services; Public Health Service; ADAMHA, 5600 Fishers Lane, Room 11-103, Rockville, MD 20857.

Chief, Neuropharmacology Program, National Institute of Mental Health; Division of Basic Brain & Behavioral Sciences; Psychopharmacology Research Branch, GM-13/14: Incumbent is responsible for planning, developing, and administering programs of support for the Neuropharmacology Program. The applicant is responsible for analyzing current research activities; identifying extramural research areas of underdevelopment; and stimulating the submission of grant applications in the Branch. Position is available immediately; salary \$46,210-70,987. Applicants must document possession of state-of-the-art knowledge of advanced theories, principles, emerging trends, methods, and techniques pertaining to the fields of psychopharmacology and neurology, and skill in the application of this knowledge to the study of neuropharmacology. Postdoctoral (or equivalent) research experience is also required. Representative: Stephen H. Koslow, Ph.D., Department of Health and Human Services; Public Health Service; ADAMHA, 5600 Fishers Lane, Room 11-103, Rockville, MD 20857.

Postdoctoral Fellowship: A staff fellow position is available immediately in the Biology of Dependence Laboratory, Clinical Pharmacology Branch, Addiction Research Center, NIDA. Primary research focus will be assessment of effects of various psychoactive drugs on human psychomotor and cognitive functioning. Other projects include drug discrimination and drug self-administration. Didactic training in drug abuse and behavioral pharmacology available. Ph.D. in experimental psychology, pharmacology, or related field. Salary range \$25,000-\$45,000, commensurate with experience. Application deadline is 6/15/92. Send letter of interest and CV to Stephen J. Heishman, Ph.D., NIDA Addiction Research Center, P. O. Box 5180, Baltimore, MD 21224 or call (410) 550-1547. NIDA is an Equal Opportunity Employer; ADAMHA is smoke-free and drug-free.

NIAAA-funded Postdoctoral Research Fellowship in Alcohol Research: The overall purpose is to provide postdoctoral training for individuals who wish to pursue a career in alcohol research, with an emphasis on the etiology and prevention of problem drinking and alcoholism. As this topic will be approached from both psychosocial and biobehavioral perspectives, individuals with background training in any relevant areas of psychology (clinical, (cont. on p. 7)

health psychology, physiological, social, cognitive, behavioral pharmacology, etc.) are encouraged to apply. Appointment is for two years, beginning in 7/92 or 9/92. Stipends begin at \$18,600 and increase with postdoctoral experience. Applicants should submit a cover letter indicating areas of research interest, CV, and 3 letters of recommendation by 5/1/92, to Alan Marlatt, Ph.D., Director, Addictive Behaviors Research Center, Department of Psychology NI-25, University of Washington, Seattle, WA, 98195.

Postdoctoral Research Fellowships: National Research Service Awards are available at the Alcohol and Drug Abuse Research Center, McLean Hospital (an affiliate of Harvard Medical School and Massachusetts General Hospital), in a multidisciplinary research program that includes basic, clinical, and treatment research. Trainees may participate in research on the behavioral pharmacology of substance abuse; neuroendocrine consequences of cocaine and alcohol abuse; effects of drug abuse on the brain as assessed by brain imaging techniques (MRI, MRS, SPECT, and EEG) and the evaluation of the safety and effectiveness of new pharmacotherapies for the treatment of drug abuse. Clinical research programs emphasize analysis of antecedents and consequences of drug abuse by women. Ph.D., M.D., or M.D./Ph.D. is required; salary commensurate with experience (PGY 1-7). Send CV, reprints of recent papers, brief statement about your research interests and goals, and names of 3 references (including address and telephone) to Dr. Jack H. Mendelson, Prof. of Psychiatry (Neuroscience) or Dr. Nancy K. Mello, Prof. of Psychology (Neuroscience), Co-Directors, Alcohol and Drug Abuse Research Center, McLean Hospital, 115 Mill St., Belmont, MA 02178. Equal Opportunity/Affirmative Action Employer.

NIDA-funded Pre- and Postdoctoral Research Traineeships in Genetics of Drug Use and Abuse: Program will train interdisciplinary scholars who can bring to bear concepts and methods of both quantitative and molecular genetics in conjunction with behavioral science perspectives in research on problems of drug use and abuse. During the 5 years of the program, 7 predoctoral and 10 postdoctoral trainees will be supported. Predoctoral trainees will pursue doctoral degrees in either Biobehavioral Health or in Genetics, with a minor emphasis in the other area. Postdoctoral fellowships will be individually designed to complement their specialty training and prepare them for effective independent and collaborative study in behavioral and pharmacological genetics of substance use and abuse. Training faculty are committed to interdisciplinary research and training and have long histories of collaboration. Trainees will be joining tightly integrated research team with strong complementary expertise. For further information, contact the Program in Biobehavioral Health, PA State Univ., East 210 Health and Human Development Bldg., University Park, PA 16802, (814) 863-7256.

Assistant Professor (2 openings): Over the next 5 years, Memorial Sloan-Kettering Cancer Center (Cornell Univ. Med. Center) will devote increasing effort to the study of biobehavioral factors in cancer and its treatment. To that end, 2 entry-level, tenure-track faculty positions have been established in the Dept. of Neurology (Psychiatry). Research areas include 1) psychoneuroimmunology (emphasis on classically conditioned immune modulations in cancer patients), 2) aversion reactions in chemotherapy patients (role of conditioning in food aversions, anticipatory side effects and immune modulation in cancer chemotherapy patients), 3) psychosocial factors in psychological, biological adjustment to cancer treatment (role of marital interaction),

4) parent-child interaction and treatment cooperation in pediatric oncology. Positions open immediately. Salary commensurate with experience. Housing available. Write to Dr. William H. Redd, Box 547, 1275 York Ave., New York, NY 10021, or: 1) Individuals with strong research record in biological mechanisms underlying psychological and behavioral factors in humans and/or in animal models. Experience in psychoneuroimmunology preferred; specific oncology experience not required. Send letter and CV to Dr. Dana H. Bovbjerg, Box 457, 1275 York Ave., New York, NY 10021. 2) Individuals interested in contribution of psychological factors and conditions to biological (i.e., immune) function in people at high risk for cancer. Ph.D. from a variety of areas (social, personality and clinical psychology) will be considered. Send letter and CV to Dr. Paul B. Jacobsen, Box 541, 1275 York Ave., NY 10021. Equal Opportunity employer, M/F/H/V.

Postdoctoral Fellowship in Psycho-Oncology: 2-year NCI-funded research fellowship provides training in research on psychiatric and psychological issues in oncology. Ph.D. in psychology with 2 years additional experience in a medicine, behavioral, or health psychology subspecialty or M.D. residency in psychiatry, neurology, or medicine required. Program integrates clinical experience with training in research design, methods of assessment, basic established investigators on funded research projects and have an opportunity to develop their own projects. Faculty are affiliated with the Dept. of Psychiatry, Cornell University Med. College. Minorities are encouraged to apply. Application forms, CV, and information requests should be directed to Mr. John Blanchette, Fellowship Representative, Psychiatry Service, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021; tel. (212) 639-8010, FAX (212) 717-3296.

Postdoctoral Clinical Research Fellowships: Several positions available (Ph.D., M.D.) in multidisciplinary research training program in the addictions. Objective is to provide comprehensive training in research techniques, including those of direct relevance to clinical research. Weekly clinical/research seminars and a year-long fundamentals course on substance abuse. Current research areas include clinical pharmacology, psychiatric comorbidity, guided self-change and community interventions, behavioral change and relapse prevention, youth and family, clinical practice and health care systems, neurocognitive, and preclinical pharmacology and experimental psychology. Available beginning 7/92, for duration of up to 2 years. Salary \$26,790-\$30,510 (Canadian), depending on postdoctoral experience. Send CV, 3 letters of reference, and brief statement of career plans and reasons for seeking training to Dr. Linda C. Sobell, Asst. Director of Research and Training, Clinical Research and Treatment Institute (CRTI), Addiction Research Foundation, 33 Russell St., Toronto, Ontario M5S 2S1, CANADA by 5/20/92. For further information, tel. 416-595-6002.

Postdoctoral Research Fellowship for Studies of the Biologic Effects of Alcohol and Other Addictive Drugs: Research done during this two-year fellowship may be conducted in any Mayo setting. There is also the opportunity to do epidemiological research. Applicants must have M.D., Ph.D., or equivalent degree, with or without postdoctoral training. Write by May 1 (date flexible for external candidates) to Dr. Steven Brimjoin, Chair, Personnel Subcommittee of the Research Committee, Mayo Clinic, 200 First St., SW, Rochester, MN 55905, with copy to Richard D. Hurt, M.D., c/o Nicotine Dependence Center, same address.

DIVISION 28 OFFICERS:*Elected:*

President	Ronald W. Wood (914) 351-4249	8/90-8/93
President-Elect	Maxine Stitzer (301) 550-0042	8/91-8/94
Past-President	Klaus Miczek (617) 381-3414	8/89-8/92
Council Representative	Stephen C. Fowler (601) 232-7383	2/91-1/94
Members-at-large	Robert Sprague (217) 333-4123	8/89-8/92
	Marilyn E. Carroll (612) 626-6289	8/90-8/93
	Alice M. Young (313) 577-3290	9/91-8/94

Appointed:

Treasurer	Jack E. Henningfield (301) 550-1494	8/91-8/94
Secretary	Stephen T. Higgins (802) 660-3066	8/91-8/93
Program Chair, 1992	Nancy Aton (301) 955-3135	8/90-8/93
Past-Program Chair	David Penetar (301) 427-5521	8/89-8/92
Incoming Program Chair	Harriet Dewit (312) 702-1537	8/91-8/94
Newsletter Editor	Cynthia S. Pomerleau (313) 764-7152	8/91-8/94

Membership Chair	Warren Bickel (802) 660-3067	8/91-8/94
CPDD Liaison	Roy Pickens (301) 443-6697	
Public Information	OPEN	
ASPET Liaison Officers	Alice M. Young (313) 577-3290	8/91-8/93
APA Public Affairs Liaison	George E. Bigelow (301) 550-0035	8/91-8/94
APS Liaison	Donald Overton (215) 787-1534	8/91-8/92
Committee on Nominations	Larry D. Byrd (404) 727-7730	8/91-8/94
Neurobehavioral Tox. Committee	Robert L. Balster (804) 786-8402	8/91-8/93
Committee on Animal Research	Hugh L. Evans (914) 351-4249	8/91-8/92
Committee on Prescript. Priv.	Marlyne Kilbey (313) 577-2802	8/91-8/94
Centennial Officer	Herbert Barry (412) 648-8563	8/91-8/93
Committee on Cont. Education	C.E. Johanson (301) 295-3470	8/91-8/94
Women's Network Representative	Carolyn Mazure (203) 785-2159	4/91-8/93

NEWSLETTER DEADLINES (*Newsletter* appears 4-6 weeks later):

Fall issue:	September 15	Spring Issue:	March 15
Winter issue:	December 15	Summer Issue:	June 15

Cynthia S. Pomerleau, Ph.D.
 Editor, *Division 28 Newsletter*
 Behavioral Medicine Program
 University of Michigan Department of Psychiatry
 Riverview Building, 900 Wall Street
 Ann Arbor, MI 48105